AJ
Therapeutic Areas
Aytu BioScience Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EXXUA™ (gepirone ER) | Major Depressive Disorder (MDD) | Approved |
| Adzenys XR-ODT® | Attention Deficit Hyperactivity Disorder (ADHD) | Approved |
| Cotempla XR-ODT® | Attention Deficit Hyperactivity Disorder (ADHD) | Approved |
| ADHD Portfolio (Other) | Attention Deficit Hyperactivity Disorder (ADHD) | Approved |
| Pediatric Portfolio (e.g., NatruSmile™, Karbinal™ ER) | Various (Fluoride Deficiency, Allergies) | Approved |
Leadership Team at Aytu BioScience
JD
Josh Disbrow
Chief Executive Officer
RS
Ryan Selhorn
Chief Financial Officer
GP
Greg Pyszczymuka
Chief Commercial Officer
JD
Jarrett Disbrow
Chief Business Officer
DG
Dr. Gerwin Westfield
Senior VP of Scientific Affairs
MC
Margaret Cabano
Senior VP of Operations
SK
Suzane Kennedy
VP of Regulatory Affairs and QA
JD
John Donofrio, Jr.
Chairman, Audit Committee Chair
CD
Carl Dockery
Director, Nominating & Governance Committee Chair
VL
Vivian Liu
Director, Compensation Committee Chair